drugset / Trial / NCT06791083

Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer

NCT06791083

NaSingle-groupOpen-labelTreatment

Summary

To observe and evaluate the neoadjuvant treatment of Envafolimab combined with Fruquintinib and chemotherapy for locally advanced gastric/gastroesophageal junction carcinoma

Timeline

Start
2024-06-20
Primary completion
2025-12
Completion
2027-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Envafolimab Monoclonal antibody 150 mg/m2 Other
Subject Fruquintinib Small molecule 5 mg Oral

Indications